ALCLS shifts focus to in vivo gene editing for dyslipidemias
The company said it is pivoting to in vivo gene editing and advancing.HEAL-101 and.HEAL-201 for severe dyslipidemias, with first clinical data expected in 2027–2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.